Skip to main content
Pulmonary Arterial Hypertension
Disease State Hub
Menu
Menu
Main navigation
Home
Education
Featured Diseases & Conditions
Acute Hepatic Porphyria
Alzheimer Disease
Chronic Lymphocytic Leukemia
COVID-19
Depression Care 360
Diabetes Technology
Digital Health Solutions in Diabetes
HER2-Positive Early Breast Cancer
HIV Management
Primary Hyperoxaluria
Ulcerative Colitis
Resources
Atlas of Lumps and Bumps
Case Presentations
Commentary
Disease State and Specialty Directory
FDA Alerts
Pearls
Podcasts
Polls
Q&A
Quizzes
Research Summaries
Slideshows
Videos
Multidisciplinary Roundtables
Featured Conferences
ACR Convergence
AIBD
American Heart Association Scientific Sessions
American Society of Hematology Annual Meeting & Exposition
Consultant360's Practical Updates in Primary Care
Conference on Retroviruses and Opportunistic Infections
Infectious Diseases Society of America’s IDWeek
Society of Gynecologic Oncology Annual Meeting
International AIDS Conference
Society of Hematologic Oncology's Annual Meeting
Clinical Updates
Allergic Asthma
Alzheimer Disease
Cardiovascular Disease
Endometrial Cancer
Endometriosis
Eosinophilic Disorders
Exocrine Pancreatic Insufficiency
Generalized Pustular Psoriasis
Major Depressive Disorder
Nasal Polyps
Ovarian Cancer
Rheumatoid Arthritis
Schizophrenia
Ulcerative Colitis
Publication
About Consultant
Advertising With Consultant360
Author Guidelines
Call for Papers
Case Report Templates
Consultant Current Issue
Consultant Archive
Consultant Early View
FAQ
Job Board
Search
Contact
Login
Menu
Menu
Main navigation
Home
Education
Featured Diseases & Conditions
Acute Hepatic Porphyria
Alzheimer Disease
Chronic Lymphocytic Leukemia
COVID-19
Depression Care 360
Diabetes Technology
Digital Health Solutions in Diabetes
HER2-Positive Early Breast Cancer
HIV Management
Primary Hyperoxaluria
Ulcerative Colitis
Resources
Atlas of Lumps and Bumps
Case Presentations
Commentary
Disease State and Specialty Directory
FDA Alerts
Pearls
Podcasts
Polls
Q&A
Quizzes
Research Summaries
Slideshows
Videos
Multidisciplinary Roundtables
Featured Conferences
ACR Convergence
AIBD
American Heart Association Scientific Sessions
American Society of Hematology Annual Meeting & Exposition
Consultant360's Practical Updates in Primary Care
Conference on Retroviruses and Opportunistic Infections
Infectious Diseases Society of America’s IDWeek
Society of Gynecologic Oncology Annual Meeting
International AIDS Conference
Society of Hematologic Oncology's Annual Meeting
Clinical Updates
Allergic Asthma
Alzheimer Disease
Cardiovascular Disease
Endometrial Cancer
Endometriosis
Eosinophilic Disorders
Exocrine Pancreatic Insufficiency
Generalized Pustular Psoriasis
Major Depressive Disorder
Nasal Polyps
Ovarian Cancer
Rheumatoid Arthritis
Schizophrenia
Ulcerative Colitis
Publication
About Consultant
Advertising With Consultant360
Author Guidelines
Call for Papers
Case Report Templates
Consultant Current Issue
Consultant Archive
Consultant Early View
FAQ
Job Board
Advertisement
Treatment
Pop Quiz: PAH Treatment
Copied to clipboard
<section><h2></h2></section><section><h2><p><span style="color: black;">The American College of Chest Physicians’ “</span><a href="https://journal.chestnet.org/article/S0012-3692(19)30002-9/fulltext" target="_blank">Therapy for Pulmonary Arterial Hypertension in Adults</a><span style="color: black;">” was updated in March 2019. According to the new recommendations, which of the following treatments is recommended to improve the 6-minute walk distance of treatment-naïve patients with pulmonary arterial hypertension (PAH) who are functional class II or III based on World Health Organization (WHO) standards? </span><strong></strong></p></h2></section><section><h2><p>Better luck next time</p></h2><p><p><span style="color: black;">The guideline also </span><a href="https://www.chestnet.org/News/Press-Releases/2019/02/PAH-guidelines" target="_blank">recommend</a>s<span style="color: black;"> that stable or symptomatic patients with PAH taking background therapy with ambrisentan should add tadalafil to their treatment regimen to improve the 6-minute walk distance.</span></p><p><br></p><p><span style="color: black;">For more PAH content, visit the </span><a href="https://www.consultant360.com/specialty/pulmonology/pulmonary-arterial-hypertension" target="_blank">Resource Center</a>.</p></p></section><section><h3><p>Nice job!</p></h3><p><p><span style="color: black;">The guideline also </span><a href="https://www.chestnet.org/News/Press-Releases/2019/02/PAH-guidelines" target="_blank">recommend</a>s<span style="color: black;"> that stable or symptomatic patients with PAH taking background therapy with ambrisentan should add tadalafil to their treatment regimen to improve the 6-minute walk distance.</span></p><p><br></p><p><span style="color: black;">For more PAH content, visit the </span><a href="https://www.consultant360.com/specialty/pulmonology/pulmonary-arterial-hypertension" target="_blank">Resource Center</a>.</p></p></section>
advertisement
Advertisement
Advertisement
